Your browser doesn't support javascript.
loading
Emerging role of RNA interference in immune cells engineering and its therapeutic synergism in immunotherapy.
Monty, Masuma Akter; Islam, Md Ariful; Nan, Xu; Tan, Jingwen; Tuhin, Israth Jahan; Tang, Xiaowen; Miao, Miao; Wu, Depei; Yu, Lei.
Afiliação
  • Monty MA; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
  • Islam MA; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
  • Nan X; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
  • Tan J; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
  • Tuhin IJ; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
  • Tang X; The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Miao M; The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Wu D; The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Yu L; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
Br J Pharmacol ; 178(8): 1741-1755, 2021 04.
Article em En | MEDLINE | ID: mdl-33608889
RNAi effectors (e.g. siRNA, shRNA and miRNA) can trigger the silencing of specific genes causing alteration of genomic functions becoming a new therapeutic area for the treatment of infectious diseases, neurodegenerative disorders and cancer. In cancer treatment, RNAi effectors showed potential immunomodulatory actions by down-regulating immuno-suppressive proteins, such as PD-1 and CTLA-4, which restrict immune cell function and present challenges in cancer immunotherapy. Therefore, compared with extracellular targeting by antibodies, RNAi-mediated cell-intrinsic disruption of inhibitory pathways in immune cells could promote an increased anti-tumour immune response. Along with non-viral vectors, DNA-based RNAi strategies might be a more promising method for immunomodulation to silence multiple inhibitory pathways in T cells than immune checkpoint blockade antibodies. Thus, in this review, we discuss diverse RNAi implementation strategies, with recent viral and non-viral mediated RNAi synergism to immunotherapy that augments the anti-tumour immunity. Finally, we provide the current progress of RNAi in clinical pipeline.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article